ESR1 and breast cancer: With regard to this pro-tumorigenic mammary gland interaction between IGF1R and ERα activation, our CTS findings with respect to HR+ breast cancer development are consistent with those of Winder et al. who found better outcomes for women with ER+ breast cancers treated with the antiestrogen tamoxifen who carry the T allele of rs2016347 [26].